Murphy Pohlad Asset Management LLC Has $1.68 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Murphy Pohlad Asset Management LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,600 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,682,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. SteelPeak Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 692 shares during the period. Atria Investments Inc increased its stake in Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after purchasing an additional 941 shares in the last quarter. Tri Locum Partners LP increased its stake in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares in the last quarter. Nordea Investment Management AB increased its stake in Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after purchasing an additional 5,495 shares in the last quarter. Finally, Tidal Investments LLC increased its stake in Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada reduced their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,090.24.

Regeneron Pharmaceuticals Price Performance

REGN opened at $843.60 on Friday. The firm has a market cap of $93.00 billion, a P/E ratio of 22.34, a PEG ratio of 3.17 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a 50-day moving average of $1,058.43 and a 200 day moving average of $1,038.87.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.79 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.